{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:25:40Z","timestamp":1793057140631,"version":"4.5.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_crpm-2024-0040_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Haemolytic disease of the fetus and newborn (HDFN) occurs due to maternal IgG alloantibodies that actively cross the placenta and bind to paternally derived fetal antigens on the erythrocytes. The aims of this study were to describe the Slovenian cohort of patients with severe HDFN, who required fetal treatment, to review the fetal treatment strategies, and to describe pregnancy and neurodevelopmental outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_crpm-2024-0040_abs_002\">\n                    <jats:title>Case series presentation<\/jats:title>\n                    <jats:p>Data on patients who developed severe HDFN between 2006 and 2021 and were treated at our institution were collected retrospectively. Primary care pediatricians were contacted regarding neurodevelopmental outcomes of surviving infants. There were 19 pregnancies affected with severe HDFN. The most commonly implicated antigen was RhD. Seventeen children were liveborn. Sixteen fetuses were treated with intrauterine transfusion (IUT). Two children had developmental delay at the corrected age of 2\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_crpm-2024-0040_abs_003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, the Slovenian national cohort of severe cases of HDFN is described for the first time. Prevalence of RhD alloimmunization was higher in comparison to the literature. A combined treatment with therapeutic plasmapheresis, immunoglobulins and IUT was successful. Three quarters of newborns were born in the late preterm period. Overall survival rate and long-term neonatal adverse outcomes in our cohort were in line with the literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/crpm-2024-0040","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T08:05:53Z","timestamp":1749456353000},"source":"Crossref","is-referenced-by-count":1,"title":["Fetal treatment and long-term neonatal outcomes in severe maternal red cell alloimmunization\u00a0\u2013\u00a0a single-centre experience"],"prefix":"10.1515","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1214-344X","authenticated-orcid":false,"given":"Vita Andreja","family":"Mesari\u010d","sequence":"first","affiliation":[{"name":"Department of Perinatology, Division of Gynaecology and Obstetrics , 37667 University Medical Centre Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Bricl","sequence":"additional","affiliation":[{"name":"Blood Transfusion Centre of Slovenija , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Hrastar","sequence":"additional","affiliation":[{"name":"Blood Transfusion Centre of Slovenija , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilijana","family":"Kornhauser Cerar","sequence":"additional","affiliation":[{"name":"Neonatology Section, Department of Perinatology, Division of Gynaecology and Obstetrics , University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Lozar Krivec","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"},{"name":"Department of Neonatology , University Children\u2019s Hospital, University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miha","family":"Rus","sequence":"additional","affiliation":[{"name":"Neonatology Section, Department of Perinatology, Division of Gynaecology and Obstetrics , University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek P.","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology , Willem-Alexander Children\u2019s Hospital, Leiden University Medical Center , Leiden , The Netherlands"},{"name":"Department of Immunohematology Diagnostic Services , Sanquin Diagnostic Services , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Premru Sr\u0161en","sequence":"additional","affiliation":[{"name":"Department of Perinatology, Division of Gynaecology and Obstetrics , 37667 University Medical Centre Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2025122008251822636_j_crpm-2024-0040_ref_001","doi-asserted-by":"crossref","unstructured":"de Haas, M, Thurik, FF, Koelewijn, JM, van der Schoot, CE. Haemolytic disease of the fetus and newborn. Vox Sang 2015;109:99\u2013113. https:\/\/doi.org\/10.1111\/vox.12265.","DOI":"10.1111\/vox.12265"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_002","doi-asserted-by":"crossref","unstructured":"de Winter, DP, Kaminski, A, Tjoa, ML, Oepkes, D. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape. BMC Pregnancy Childbirth 2023;23:1\u201310. https:\/\/doi.org\/10.1186\/s12884-022-05329-z.","DOI":"10.1186\/s12884-022-05329-z"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_003","doi-asserted-by":"crossref","unstructured":"Lieberman, L, Callum, J, Cohen, R, Cserti-Gazdewich, C, Ladhani, NNN, Buckstein, J, et al.. Impact of red blood cell alloimmunization on fetal and neonatal outcomes: a single center cohort study. Transfusion (Paris) 2020;60:2537\u201346. https:\/\/doi.org\/10.1111\/trf.16061.","DOI":"10.1111\/trf.16061"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_004","doi-asserted-by":"crossref","unstructured":"Tyndall, C, Cuzzilla, R, Kane, SC. The rhesus incompatible pregnancy and its consequences for affected fetuses and neonates. Transfus Apher Sci 2020;59:102948. https:\/\/doi.org\/10.1016\/j.transci.2020.102948.","DOI":"10.1016\/j.transci.2020.102948"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_005","doi-asserted-by":"crossref","unstructured":"Hendrickson, JE, Delaney, M. Hemolytic disease of the fetus and newborn: modern practice and future investigations. Transfus Med Rev 2016;30:159\u201364. https:\/\/doi.org\/10.1016\/j.tmrv.2016.05.008.","DOI":"10.1016\/j.tmrv.2016.05.008"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_006","doi-asserted-by":"crossref","unstructured":"Zwiers, C, van Kamp, I, Oepkes, D, Lopriore, E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn\u2013review on current management and outcome. Expert Rev Hematol 2017;10:337\u201344. https:\/\/doi.org\/10.1080\/17474086.2017.1305265.","DOI":"10.1080\/17474086.2017.1305265"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_007","doi-asserted-by":"crossref","unstructured":"Visser, GHA, Thommesen, T, Di Renzo, GC, Nassar, AH, Spitalnik, SL, Nassar, A, et al.. FIGO\/ICM guidelines for preventing rhesus disease: a call to action. Int J Gynecol Obstet 2021;152:144\u20137. https:\/\/doi.org\/10.1002\/ijgo.13459.","DOI":"10.1002\/ijgo.13459"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_008","doi-asserted-by":"crossref","unstructured":"Delaney, M, Matthews, DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus and newborn. Hematology: Am Soc Hematology Educ Progr 2015:145\u201351.","DOI":"10.1182\/asheducation-2015.1.146"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_009","doi-asserted-by":"crossref","unstructured":"Mari, G, Norton, ME, Stone, J, Berghella, V, Sciscione, AC, Tate, D, et al.. Society for maternal-fetal medicine (SMFM) clinical guideline #8: the fetus at risk for anemia-diagnosis and management. Am J Obstet Gynecol 2015;212:697\u2013710. https:\/\/doi.org\/10.1016\/j.ajog.2015.01.059.","DOI":"10.1016\/j.ajog.2015.01.059"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_010","doi-asserted-by":"crossref","unstructured":"Zwiers, C, van der Bom, JG, van Kamp, IL, van Geloven, N, Lopriore, E, Smoleniec, J, et al.. Postponing early intrauterine transfusion with intravenous immunoglobulin treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol 2018;219:291.e1\u2013291.e9. https:\/\/doi.org\/10.1016\/j.ajog.2018.06.007.","DOI":"10.1016\/j.ajog.2018.06.007"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_011","doi-asserted-by":"crossref","unstructured":"Ruma, MS, Moise, KJ, Kim, E, Murtha, AP, Prutsman, WJ, Hassan, SS, et al.. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol 2007;196:138.e1\u2013138.e6. https:\/\/doi.org\/10.1016\/j.ajog.2006.10.890.","DOI":"10.1016\/j.ajog.2006.10.890"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_012","doi-asserted-by":"crossref","unstructured":"Garabedian, C, Rakza, T, Thomas, D, Wibaut, B, Vaast, P, Subtil, D, et al.. Neonatal outcome after fetal anemia managed by intrauterine transfusion. Eur J Pediatr 2015;174:1535\u20139. https:\/\/doi.org\/10.1007\/s00431-015-2573-x.","DOI":"10.1007\/s00431-015-2573-x"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_013","doi-asserted-by":"crossref","unstructured":"De Winter, D, Hulzebos, C, Van \u2019t Oever, R, De Haas, M, Verweij, E, Lopriore, E. History and current standard of postnatal management in hemolytic disease of the fetus and newborn. Eur J Pediatr 2022;182:489\u2013500. https:\/\/doi.org\/10.1007\/s00431-022-04724-0.","DOI":"10.1007\/s00431-022-04724-0"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_014","doi-asserted-by":"crossref","unstructured":"Solheim, BG, Gr\u00f6nn, M, Hansen, TWR. Hemolytic disease of the fetus and newborn. Rossi\u2019s Principles Transfus Med 2016:528\u201334. https:\/\/doi.org\/10.1002\/9781119013020.ch45.","DOI":"10.1002\/9781119013020.ch45"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_015","unstructured":"Rojeni in umrli [Internet]. 2023. Available from: https:\/\/www.stat.si\/StatWeb\/Field\/Index\/17\/95."},{"key":"2025122008251822636_j_crpm-2024-0040_ref_016","doi-asserted-by":"crossref","unstructured":"Pan, W, Wu, H, Chen, J, Mo, X, Wang, H, Fang, Q, et al.. Fetal and neonatal outcome in severe alloimmunization managed with intrauterine transfusion: 18-year experience in a tertiary referral hospital in China. Front Pediatr 2023;11:1\u20137. https:\/\/doi.org\/10.3389\/fped.2023.1157004.","DOI":"10.3389\/fped.2023.1157004"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_017","doi-asserted-by":"crossref","unstructured":"Voto, LS, Mathet, ER, Zapaterio, JL, Orti, J, Lede, RL, Margulies, M. High-dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): a new alternative for the treatment of severe fetal hemolytic disease. J\u00a0Perinat Med 1997;25:85\u20138. https:\/\/doi.org\/10.1515\/jpme.1997.25.1.85.","DOI":"10.1515\/jpme.1997.25.1.85"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_018","doi-asserted-by":"crossref","unstructured":"Bellone, M, Boctor, FN. Therapeutic plasma exchange and intravenous immunoglobulin as primary therapy for D alloimmunization in pregnancy precludes the need for intrauterine transfusion. Transfusion (Paris) 2014;54:2118\u201321. https:\/\/doi.org\/10.1111\/trf.12633.","DOI":"10.1111\/trf.12633"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_019","doi-asserted-by":"crossref","unstructured":"Nwogu, LC, Moise, KJ, Klein, KL, Tint, H, Castillo, B, Bai, Y. Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion. Transfusion (Paris) 2018;58:677\u201384. https:\/\/doi.org\/10.1111\/trf.14453.","DOI":"10.1111\/trf.14453"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_020","unstructured":"Pasman, SA, Claes, L, Lewi, L, Van Schoubroeck, D, Debeer, A, Emonds, M, et al.. Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14\u00a0years experience in Leuven. Facts Views Vis Obgyn 2015;7:129\u201336."},{"key":"2025122008251822636_j_crpm-2024-0040_ref_021","doi-asserted-by":"crossref","unstructured":"Teune, MJ, Bakhuizen, S, Bannerman, CG, Opmeer, BC, Van Kaam, AH, Van Wassenaer, AG, et al.. A systematic review of severe morbidity in infants born late preterm. Am J Obstet Gynecol 2011;205:374.e1\u2013374.e9. https:\/\/doi.org\/10.1016\/j.ajog.2011.07.015.","DOI":"10.1016\/j.ajog.2011.07.015"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_022","doi-asserted-by":"crossref","unstructured":"Joy, SD, Rossi, KQ, Krugh, D, O\u2019Shaughnessy, RW. Management of pregnancies complicated by anti-E alloimmunization. Obstet Gynecol 2005;105:24\u20138. https:\/\/doi.org\/10.1097\/01.aog.0000149153.93417.66.","DOI":"10.1097\/01.AOG.0000149153.93417.66"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_023","doi-asserted-by":"crossref","unstructured":"McGowan, EC, Vohr, BR. Neurodevelopmental follow-up of preterm infants: what is new? Pediatr Clin North Am 2019;66:509\u201323. https:\/\/doi.org\/10.1016\/j.pcl.2018.12.015.","DOI":"10.1016\/j.pcl.2018.12.015"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_024","doi-asserted-by":"crossref","unstructured":"Arcangeli, T, Thilaganathan, B, Hooper, R, Khan, KS, Bhide, A. Neurodevelopmental delay in small babies at term: a systematic review. Ultrasound Obstet Gynecol 2012;40:267\u201375. https:\/\/doi.org\/10.1002\/uog.11112.","DOI":"10.1002\/uog.11112"},{"key":"2025122008251822636_j_crpm-2024-0040_ref_025","doi-asserted-by":"crossref","unstructured":"Lindenburg, IT, Smits-Wintjens, VE, Van Klink, JM, Verduin, E, Van Kamp, IL, Walther, FJ, et al.. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus\/newborn: the LOTUS study. Am J Obstet Gynecol 2012;206:141.e1\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2011.09.024.","DOI":"10.1016\/j.ajog.2011.09.024"}],"container-title":["Case Reports in Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/crpm-2024-0040\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/crpm-2024-0040\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:25:31Z","timestamp":1766219131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/crpm-2024-0040\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,9]]},"published-print":{"date-parts":[[2025,1,29]]}},"alternative-id":["10.1515\/crpm-2024-0040"],"URL":"https:\/\/doi.org\/10.1515\/crpm-2024-0040","relation":{},"ISSN":["2192-8959"],"issn-type":[{"value":"2192-8959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"20240040"}}